Overview
The Implementation of standardized IMDRF (International Medical Device Regulators Forum) codes for adverse event reporting.
Required Action: Update Standard Operating Procedures (SOPs) and Quality Management Systems (QMS).
Introduction
In December the Agency has taken a decisive step toward international harmonization by detailing the implementation of new adverse event terminology based on IMDRF standards.
The message is clear: the “language” of Techno vigilance has changed. The way we describe, code, and report failures and incidents with medical devices in Brazil is undergoing a profound restructuring to align with the world’s leading regulators.
The "New Language" of Techno Vigilance
The discussion focuses on replacing generic descriptions or internal codes with a hierarchically standardized international structure. The IMDRF proposes a set of codes that categorize incidents into logical levels, allowing for much more robust data analysis.
What does this mean in practice for manufacturers and importers?
End of Subjectivity: Instead of describing a problem in free text or broad categories, companies must use specific IMDRF codes to identify:
- Medical Device Problem;
- Type of Investigation / Cause;
- Patient Outcome;
- Component / Part.
Global Traceability: By adopting these codes, an adverse event occurring in Brazil can be automatically compared with databases in Europe or the US, facilitating the detection of global risk signals.
System Revision: Electronic Quality Management Systems (eQMS) and complaint investigation forms will need to be adapted to include fields for this new coding system.
Impacts and Deadlines
This transition is not just a change of “labeling,” but a culture shift in post-market risk analysis.
Operational Impact: Techno vigilance teams will need training to interpret and apply the correct codes. Incorrect classification could trigger unnecessary sanitary alerts or mask real risks.
Procedures (SOPs): All procedures involving Customer Service (SAC), complaint handling, and notification to Anvisa (Notivisa) must be revised.
Timeline: Although Anvisa has signaled the start of implementation, compliance efforts should begin immediately. The expectation is that the notification system will soon require these fields mandatorily, and companies that wait until the last minute will face technical difficulties in submitting mandatory reports.
Conclusion
Regulatory convergence is a one-way street. Adopting IMDRF terminology places Brazil on the same level as the most demanding regulatory agencies in the world, but it brings a complex “homework” assignment for companies. It is not just about filling out a different form, but understanding the taxonomy of the problem from a global perspective.
Is your company ready for this paradigm shift?
Do not risk non-compliance in your Techno vigilance processes. GRP has specialists who are up-to-date with IMDRF guidelines and ready to assist your team in reviewing procedures and safely implementing these new requirements. Contact us to ensure your products remain on the market in full compliance.
GRP Brazil
If you are interested in registering your products in Brazil, GRP is ready to help. Our team of experts can simplify the process of registering products in Brazil and make it easier to schedule meetings with Anvisa more efficiently.
GRP can act as your local Agent & Register your product in U.S
Contact our team today to Inquire!
Email: info@globalregulatorypartners.com
Telephone : (+1) 781-672-4200
References
Learn more about Anvisa.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations.